Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Phase Ib : To determine the MTD and/or RP2D of buparlisib + carboplatin in patients with recurrent GBM who have progressed after SoC (RT with TMZ in combination and adjuvant) regardless of PI3K pathway activation status. same objective with buparlisib + lomustine phase II : To assess anti-tumor activity of buparlisib + carboplatin combination in patients with recurrent GBM who have progressed after SoC regardless of PI3K pathway activation status. To assess anti-tumor activity buparlisib + lomustine combination compared to lomustine + placebo in patients with recurrent GBM who have progressed after SoC regardless the PI3K pathway activation
Critère d'inclusion
- recurrent glioblastoma multiform